GRAIL, Inc. (GRAL)
| Market Cap | 5.44B +87.0% |
| Revenue (ttm) | 166.60M +17.5% |
| Net Income | -406.18M |
| EPS | -9.27 |
| Shares Out | 44.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 755,914 |
| Open | 122.00 |
| Previous Close | 119.13 |
| Day's Range | 117.00 - 129.70 |
| 52-Week Range | 41.50 - 166.48 |
| Beta | 2.87 |
| Analysts | Buy |
| Price Target | 132.56 (+9.09%) |
| Earnings Date | Nov 4, 2026 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for GRAL stock is "Buy." The 12-month stock price target is $132.56, which is an increase of 9.09% from the latest price.
News
Grail price target raised to $110 from $100 at Mizuho
Mizuho raised the firm’s price target on Grail (GRAL) to $110 from $100 and keeps a Neutral rating on the shares.
Grail price target raised to $100 from $84 at RBC Capital
RBC Capital raised the firm’s price target on Grail (GRAL) to $100 from $84 and keeps a Sector Perform rating on the shares. The company’s Q3 results support the firm’s…
Grail price target lowered to $150 from $155 at Baird
Baird lowered the firm’s price target on Grail (GRAL) to $150 from $155 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results. Published…
GRAIL Earnings Call Transcript: Q3 2026
Q3 test volumes grew 24% YoY, but promotions and commercial investment pressured ASP and margins. A favorable FDA advisory vote and published trial results strengthen the case for approval and future reimbursement, with a decision expected early Q1 2027.
GRAIL Earnings release: Q3 2026
GRAIL released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
GRAIL Quarterly report: Q3 2026
GRAIL has published its Q3 2026 quarterly earnings report on November 4, 2026.
Grail reports Q3 EPS ($2.21), consensus ($1.90)
Reports Q3 revenue $37.5M, consensus $44.21M. “GRAIL (GRAL) achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee,” said Josh Of...
GRAIL Reports Third Quarter 2026 Financial Results
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Vol...
GRAIL to Present at the UBS Global Healthcare Conference
SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management ...
GRAIL to Announce Third Quarter 2026 Financial Results
SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue finan...
Grail price target raised to $180 from $88 at TD Cowen
TD Cowen raised the firm’s price target on Grail (GRAL) to $180 from $88 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics space…
Grail price target raised to $120 from $60 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Grail (GRAL) to $120 from $60 and keeps an Equal Weight rating on the shares.
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to P...
Grail price target raised to $175 from $105 at UBS
UBS raised the firm’s price target on Grail (GRAL) to $175 from $105 and keeps a Buy rating on the shares. Following the FDA panel and Centers for Medicare and…
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
An advisory panel to the US Food and Drug Administration handed Grail's Galleri blood test a milestone win last week, saying the early cancer detection test's potential benefits outweigh its risks and...
Grail price target raised to $155 from $75 at Guggenheim
Guggenheim raised the firm’s price target on Grail (GRAL) to $155 from $75 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for select…
Grail price target raised to $150 from $80 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Grail (GRAL) to $150 from $80 and keeps a Buy rating on the shares. The firm increased Grail’s revenue estimates…
Grail price target raised to $100 from $65 at Mizuho
Mizuho raised the firm’s price target on Grail (GRAL) to $100 from $65 and keeps a Neutral rating on the shares. The FDA panel voted that Galleri is safe, effective,…
Grail panel votes ‘closer than we expected,’ says BTIG
BTIG analyst Mark Massaro says following the FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee for the Galleri cancer test from Grail (GRAL) that while the…
AdCom meeting for Grail’s Galleri test better than expected, says Canaccord
Canaccord keeps a Buy rating and an $80 price target on Grail (GRAL), noting the firm remains bullish on the shares as the AdCom meeting for the company’s Galleri test…
TD ups Grail approval probability to 95% after panel vote
TD Cowen analyst Dan Brennan views the end result of the FDA panel meeting as solid for Grail (GRAL). The panel voted 7-2 with in favor of Galleri’s benefit to…
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.
Grail says FDA panel recommendations ‘reaffirm high evidence bar’ for Galleri
Grail (GRAL) announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee of the U.S. Food and Drug Administration for the approval…
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular an...
FDA panel votes in favor of Grail’s Galleri benefits outweighing risks
The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee voted to recommend approval for Grail’s (GRAL) Galleri, a blood test designed to screen for multiple types…